[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fibrinolysis-shutdown\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fibrinolysis-shutdown":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100553987","extended-perioperative-administration-of-fibrinolysis-inhibitors-after-cardiac-surgery-100553987",false,"NCT06493227","Extended Perioperative Administration of Fibrinolysis Inhibitors After Cardiac Surgery","The Practice of Routine Extended Perioperative Administration of Fibrinolysis Inhibitors to Reduce the Risk of Bleeding in Cardiac Surgery. Multicenter Prospective Randomized Cluster Crossover Study","PRIORITY","Inclusion Criteria:\n\n1. A hospital that performs a minimum of 250 open heart interventions per year.\n2. Consent from hospital physicians regarding the prophylactic use of fibrinolysis inhibitors (more than 95% of physicians involved in the treatment of adult patients (\\>18 years) agree to adhere to the strategy of using fibrinolysis inhibitors as prescribed by the study protocol).\n\nExclusion Criteria:\n\n* Hospital does not meet inclusion criteria","ALL","18 Years",{"count":20,"type":21},1373,"ESTIMATED","INTERVENTIONAL",[24],"NA","PRIORITY is a pragmatic, multi-center, cluster crossover trial that aims to evaluate whether implementing a policy of routine extended (intraoperative and 4 hour after transfer to ICU) use of fibrinolysis inhibitors leads to a decrease in post-operative blood transfusion compared to a policy that only involves intraoperative use.",[27,28,29],"Thoracic Surgery","Heart Diseases","Fibrinolysis Shutdown","RECRUITING","2025-01-22",{"date":33,"type":34},"2025-01-27","ACTUAL",{"date":36,"type":34},"2024-08-01",{"date":38,"type":21},"2026-06-01",{"name":40,"class":41},"Saint Petersburg State University, Russia","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100480811","phase-2-viscoelastic-testing-guided-tissue-plasminogen-activator-treatment-in-acute-respiratory-failure-100480811","NCT05540834","Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory Failure","A Phase 2 Safety, Dose-finding and Efficacy Study Evaluating Viscoelastic Testing (VET) Guided Tissue Plasminogen Activator (tPA) Treatment in Critically-ill Pro-thrombotic Acute Respiratory Failure","VETtiPAT-ARF","Inclusion Criteria:\n\n1. Acute respiratory failure of primary pulmonary infectious or extrapulmonary infectious aetiology with severity graded by the arterial oxygen partial pressure to inspired fraction of oxygen ratio (P\u002FF) as per the Berlin definition: acute onset of hypoxemia with an arterial partial pressure of oxygen (PaO2) to inspired fraction of oxygen (FiO2) ratio of less than or equal to 300 mmHg with positive end expiratory pressure (PEEP) of 5 cm of water (H2O) or greater\n2. Requiring admission to Intensive Care\n3. Aged 18 - 75 years of age\n4. Procoagulant profile on ClotPro (TradeMark) fibrinogen (FIB)-test +\u002F- extrinsic coagulation pathway (EX)-test - above normal range for amplitude at 10 minutes (A10) and\u002For maximal clot firmness (MCF) at 30 minutes run time\n5. Lysis Time on ClotPro tissue plasminogen activator (TPA)-test ClotPro equal to or greater than 365 seconds\n\nExclusion Criteria:\n\n1. Platelet count \\\u003C150 x 109\u002FL or a reduction in platelet count of 50% or more in the last 24 hours\n2. Body weight \\\u003C 60 kg\n3. Structural intracranial disease e.g. arterio-venous malformation or aneurysm\n4. Previous intracranial haemorrhage\n5. Ischaemic stroke within 3 months\n6. Traumatic cardiopulmonary resuscitation\n7. Hypoxaemia from traumatic lung injury\n8. Active or recent bleeding\n9. Recent surgery, trauma or invasive procedure\n10. Systolic blood pressure (BP) \\> 180 mm Hg\n11. Diastolic BP \\> 100 mm Hg\n12. Pericarditis or pericardial fluid\n13. Diabetic retinopathy\n14. Currently menstruating\n15. Pregnancy - (beta-human chorionic gonadotropin (HCG) to be performed if of child-bearing age)\n16. Liver failure (known severe liver disease or an alanine aminotransferase or an aspartate aminotransferase level that is 5 times the upper limit of normal)\n17. Kidney failure (estimated Glomerular Filtration Rate (eGFR =\\\u003C30 mL\u002Fhr or receiving renal replacement therapy)\n18. Use of therapeutic anticoagulation or platelet antagonists\n19. Not for active treatment\n20. Unlikely to survive until the day after tomorrow","75 Years",{"count":52,"type":21},70,[54],"PHASE2","Patients with coronavirus disease (COVID) and non-COVID acute respiratory failure (ARF) may be at an increased risk of thrombosis due to increased clot formation and decreased clot lysis. This two stage study aims to utilise bedside coagulation technology to detect patients at increased risk and guide tPA treatment to maximise efficacy and safety through a personalised approach.",[57,58,29],"Acute Respiratory Failure","Hypercoagulability","2024-04-15",{"date":61,"type":34},"2024-04-17",{"date":63,"type":34},"2022-05-18",{"date":65,"type":21},"2026-12-01",{"name":67,"class":41},"South West Sydney Local Health District",1]